Innate immunity predictors of HIV: the role of contraception, pregnancy and HSV-2

HIV 的先天免疫预测因素：避孕、怀孕和 HSV-2 的作用

• 批准号: 8735981
• 负责人: RAINA N. FICHOROVA
• 金额: $ 50.33万
• 依托单位: FAMILY HEALTH INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-17 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8735981
• 关键词: Advocate; Affect; African; Age; Biological; Biological Markers; Biological Response Modifiers; Blood; CCL23 gene; Cervical; Cervix Uteri; Clinical; Combined Oral Contraceptives; Complex; Conflict (Psychology); Consultations; Contraceptive Agents; Contraceptive methods; Counseling; Environment; Enzyme-Linked Immunosorbent Assay; Epidemiologic Studies; Epidemiology; Equilibrium; Estrogens; Exposure to; Female; Genital system; Goals; Guidelines; HIV; HIV Infections; HIV risk; HIV-1; Health Policy; High Prevalence; Hormonal; Hormones; Human Herpesvirus 2; IL6 gene; IL8 gene; Immune; Immune system; Immunity; Immunologics; Immunosuppressive Agents; Incidence; Infection; Inflammation; Inflammation Mediators; Inflammatory; Injectable; Intercellular adhesion molecule 1; Interleukin-1; Interleukin-6; Interleukin-7; Laboratories; Measures; Mediator of activation protein; Medroxyprogesterone 17-Acetate; Menstrual cycle; Natural Immunity; Outcome; Participant; Phase; Policy Maker; Pregnancy; Progesterone; Progestins; Prospective Studies; Public Health; RANTES; Research; Research Design; Risk; Risk Factors; Role; SHBG gene; SLPI gene; Sampling; Serum; Sex Hormone-Binding Globulin; Site; Specific qualifier value; Specimen; Swab; Testing; Time; Translating; Uganda; Vascular Endothelial Growth Factors; Vulnerable Populations; Woman; World Health Organization; Zimbabwe; activin A; beta-defensin-2; condoms; evidence base; experience; health practice; hormonal contraception; immune activation; longitudinal analysis; novel; prevent; public health relevance; reproductive; reproductive hormone; transmission process; unintended pregnancy

DESCRIPTION (provided by applicant): Hormonal contraception (HC), including the injectable progestin depot medroxyprogesterone acetate (DMPA) and combined oral contraceptives (COCs), and pregnancy have been associated with increased risk of HIV in some, but not all, large prospective studies. In February 2012, due to the conflicting epidemiologic study results and lack of sufficient mechanistic information, the World Health Organization held a technical consultation to evaluate the existing evidence on hormonal contraception and HIV infection. The WHO decided not to change the guidelines for access to HC for women at risk of HIV but recommended that women who specifically use progestin-only injectable contraception and seek to prevent unintended pregnancy and HIV should be strongly advised to also use condoms for dual protection. Policy makers and women's advocate groups have expressed concern that the WHO statement is insufficient and difficult to translate into effective counseling for women. In addition, genital HSV-2 infection is known to significantly increase a woman's risk of acquiring HIV, but the mechanism and the impact of hormones on this relationship are not understood. A more complete mechanistic understanding of how HC and HSV-2 may modify the female immune system to increase the risk of HIV is key to clarifying the results of the epidemiologic studies and to establishing more accurate and effective public health policy and practice. The aims of the proposed research are two-fold: 1) to understand the associations between systemic hormonal levels, circulating regulators of inflammation and immunity and soluble innate immunity mediators in the cervix, their relationship with HIV acquisition risk, and how these relationships are altered by exposure to hormonal contraception (DMPA and COC) and pregnancy; and 2) to define the effects of pregnancy and hormonal contraception on the innate immune system preceding, at the time of, and during established (> 6 months) HSV-2 infection to better understand the effect of hormonal contraception and pregnancy on HSV-2 associated HIV risk. We will use ~4,000 longitudinal paired serum and cervical specimens from 1,200 women from Uganda and Zimbabwe who used DMPA, COCs and no hormonal contraception and participated in the HC-HIV study with well-specified HIV and HSV-2 seroconversion dates and who experienced substantial HSV-2, HIV-1 and pregnancy incidence. We will use ELISA and the Meso Scale Discovery multiplex platform to measure levels of endogenous hormones and regulators of inflammation and immunity in cervical samples and paired blood serum. We will use cross-sectional and longitudinal analyses to determine how hormonal contraception, pregnancy and menstrual cycle modify innate immunity, how systemic regulators affect the cervical immune environment, and how the immune regulators are associated with HSV-2 infection (incident and prevalent) and subsequent HIV acquisition risk. This research provides a unique opportunity to elucidate and validate the complex associations between endogenous and exogenous hormones, HSV-2 and HIV-1 through analysis of underlying shared biological mechanisms.

描述（由申请人提供）：在一些（但不是全部）大型前瞻性研究中，激素避孕（HC），包括注射黄体酮醋酸甲羟黄体酮（DMPA）和联合口服避孕药（COCs），以及怀孕与HIV风险增加有关。2012年2月，由于流行病学研究结果相互矛盾和缺乏足够的机制信息，世界卫生组织举行了一次技术协商，以评估关于激素避孕和艾滋病毒感染的现有证据。世卫组织决定不改变艾滋病毒风险妇女获得HC的指导方针，但建议强烈建议专门使用孕激素注射剂避孕并寻求预防意外怀孕和艾滋病毒的妇女也使用避孕套，以提供双重保护。政策制定者和妇女倡导团体对世卫组织的声明不够充分，难以转化为对妇女的有效咨询表示关切。此外，生殖器2型单纯疱疹病毒感染已知会显著增加妇女感染的风险